Capricor Therapeutics has announced that it has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of its exosome technology portfolio. Exosome-based therapy is an exciting area for Duchenne muscular dystrophy. We hope it will become the next generation of gene therapy without immunity issues.

We will be keeping a close eye on this technology and look forward to sharing it with the Canadian Duchenne community.

Click the button below to read the full press release.